Ponesimod in adults with moderate-to-severe chronic plaque psoriasis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open-label Phase 3 trial evaluates the safety and potential benefit of ponesimod in adults with moderate-to-severe chronic plaque psoriasis. Eligible participants have a body surface area involvement of at least 10%, a PASI of 12 or higher, and a PGA of 3 or more. The study is conducted at Vanda investigational sites in Glendale, AZ; Fremont, CA; and Miami, FL. Participants will receive ponesimod and will be monitored for safety and treatment response over a defined period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male and female subjects aged 18-65 years, inclusive
* BMI \>18 and \<40
* Minimum affected BSA of 10%
* PASI score ≥ 12
* PGA ≥ 3
* Diagnosed with moderate-to-severe plaque psoriasis

Exclusion Criteria:

* Diagnosis of generalized erythrodermic, generalized pustular (von Zumbusch), guttate, or palmoplantar psoriasis
* History of an allergic reaction or known and/or significant sensitivity to study drug

Where it's running

• Vanda Investigational Site
  Glendale, Arizona, United States Recruiting
• Vanda Investigational Site
  Fremont, California, United States Recruiting
• Vanda Investigational Site
  Miami, Florida, United States Recruiting
• Vanda Investigational Site
  Indianapolis, Indiana, United States Recruiting
• Vanda Investigational Site
  Portsmouth, New Hampshire, United States Recruiting
• Vanda Investigational Site
  Rochester, New York, United States Recruiting

Study contacts

• Study coordinator: Vanda Pharmaceuticals, Inc.
• Email: clinicaltrials@vandapharma.com
• Phone: 202-734-3400

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ponesimod for moderately to severely active ulcerative colitis: a treatment study

  This study tests whether ponesimod can help people with moderately to severely active ulcerative colitis who have not responded well to other treatments.

  Recruiting at 2 sites Phase 3 Vanda Pharmaceuticals · Chula Vista, California and 1 other locations · NCT07686081

• Tradipitant for GLP-1R agonist–related nausea and vomiting in adults with overweight or class I–II obesity

  This trial will test if tradipitant can reduce nausea and vomiting caused by GLP-1 receptor agonist weight-loss medicines in adults who are overweight or have class I–II obesity.

  Recruiting at 3 sites Phase 3 Vanda Pharmaceuticals · Los Angeles, California and 9 other locations · NCT07446439

• Eight-week test of VSJ-110 versus placebo for dry eye

  This eight-week test will see if VSJ-110 reduces dry eye symptoms better than a placebo in adults with dry eye.

  Recruiting at 2 sites Phase 2 Vanda Pharmaceuticals · Newport Beach, California and 4 other locations · NCT07179055

• Iloperidone for adults with uncontrolled high blood pressure

  We are testing whether iloperidone can lower blood pressure in adults whose blood pressure stays high despite at least 8 weeks of one or more blood pressure medications.

  Recruiting at 18 sites Phase 2 Vanda Pharmaceuticals · Phoenix, Arizona and 27 other locations · NCT07090161

• Testing whether stopping iloperidone long-acting injection causes symptom return in adults with schizophrenia.

  This trial tests whether iloperidone long-acting injection prevents symptom worsening compared with placebo in adults with schizophrenia.

  Recruiting at 22 sites Phase 3 Vanda Pharmaceuticals · Rogers, Arkansas and 21 other locations · NCT06961968

• Evaluating Tasimelteon for Pediatric Insomnia

  This study is testing if a new sleep medication called tasimelteon can help children and teenagers aged 2 to 17 with insomnia sleep better compared to a placebo.

  Recruiting at 34 sites Phase 3 Vanda Pharmaceuticals · Dothan, Alabama and 34 other locations · NCT06953869

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.